Human Galectin-1(LGALS1) ELISA kit

Instructions
Code CSB-EL012882HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name lectin, galactoside-binding, soluble, 1
Alternative Names 14 kDa laminin-binding protein ELISA Kit; 14 kDa lectin ELISA Kit; Beta galactoside binding lectin ELISA Kit; Beta galactoside binding lectin L 14 I ELISA Kit; beta galactoside binding protein ELISA Kit; Beta-galactoside-binding lectin L-14-I ELISA Kit; DKFZp686E23103 ELISA Kit; Gal 1 ELISA Kit; Gal-1 ELISA Kit; GAL1 ELISA Kit; Galaptin ELISA Kit; Galbp ELISA Kit; Galectin ELISA Kit; Galectin-1 ELISA Kit; Galectin1 ELISA Kit; GBP ELISA Kit; HBL ELISA Kit; HLBP14 ELISA Kit; HPL ELISA Kit; L 14.5 ELISA Kit; L-14.5 ELISA Kit; L14 ELISA Kit; Lactose binding lectin 1 ELISA Kit; Lactose-binding lectin 1 ELISA Kit; Lect14 ELISA Kit; Lectin galactoside binding soluble 1 ELISA Kit; Lectin galactoside-binding soluble 1 ELISA Kit; LEG1_HUMAN ELISA Kit; LGALS 1 ELISA Kit; LGALS1 ELISA Kit; Lgals1 lectin galactose binding soluble 1 ELISA Kit; MAPK activating protein MP12 ELISA Kit; Putative MAPK activating protein MP12 ELISA Kit; Putative MAPK-activating protein PM12 ELISA Kit; S Lac lectin 1 ELISA Kit; S-Lac lectin 1 ELISA Kit
Abbreviation LGALS1
Uniprot No. P09382
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 3.12 ng/mL-200 ng/mL
Sensitivity 0.78 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human LGALS1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 86  
Range % 80-94  
1:2 Average % 85  
Range % 80-92  
1:4 Average % 92  
Range % 87-99  
1:8 Average % 97  
Range % 90-105  
Recovery
The recovery of human LGALS1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 90 83-98  
EDTA plasma (n=4) 94 88-100  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
200 2.312 2.143 2.228 2.074  
100 1.953 1.823 1.888 1.734  
50 1.562 1.482 1.522 1.368  
25 1.198 1.134 1.166 1.012  
12.5 0.647 0.596 0.622 0.468  
6.25 0.371 0.347 0.359 0.205  
3.12 0.234 0.219 0.227 0.073  
0 0.158 0.149 0.154    
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Lectin that binds beta-galactoside and a wide array of complex carbohydrates. Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis.
Gene References into Functions
  1. Silencing Gal-1 impaired invasiveness, and decreased S1PR1 expression and overexpression in gastric cancer can promote the expression of S1PR1and invasion of gastric cancer cells. PMID: 30453284
  2. Association of galectin-1 expression with eosinophilic infiltration of the tumor tissue in stomach and colorectal cancer was detected. PMID: 29926280
  3. Study shows that recombinant Galectin-1 (Gal-1) could promote the differentiation and invasion of Trophoblast stem cells (TSCs), suggesting that some of Ishikawa cells secretion increase the expression of Gal-1 in TSCs during implantation, which then induced trophoblast differentiation and invasion in vitro. PMID: 28826368
  4. In conclusion, these findings suggest that the serum levels of Gal-1, Gal-3, and Gal-9 may be associated with large artery atherosclerotic stroke. PMID: 28112232
  5. High LGALS1 expression is associated with fibrosis in chronic pancreatitis and pancreatic cancer. PMID: 29328490
  6. Pancreatic stellate cells promote cancer proliferation, migration, and invasion via Gal1-driven pathways. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression. PMID: 29615514
  7. Studies indicate tumor-derived galectin-1, galectin-3 and galectin-9 in various cancers and anticancer therapies that target these molecules [Review]. PMID: 29389859
  8. The expression level of galectin-1 affects survival in patients with glioblastoma multiforme treated with adjuvant radiotherapy PMID: 29378529
  9. Results show that Galectin-1 teams up with Galectin-3 to induce inflammatory/pro-degradative gene signature in human chondrocytes affecting the progression of osteoarthritis. Also, Galectin-3 was found to induce a pro-degradative-inflammatory gene signature in human chondrocytes, teaming up with Galectin-1 in the pathogenesis of osteoarthritis. PMID: 27982117
  10. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. These results highlight a novel function of a human-used drug as a means of boosting the antitumor response PMID: 28512172
  11. Gal-1, Gal-3 and Gal-9 galectin expression was higher in the myenteric plexus ganglia of chagasic patients PMID: 28554765
  12. Results have shown that Gal-1 in the farnesyl-bound form acquires the ability to form self-clusters, and the galactoside-binding pocket of Gal-1 in the FTS-bound form plays an important role in self-cluster formation. PMID: 27624845
  13. Our findings support the introduction of galectin-1 as a reliable diagnostic marker for thyroid carcinomas. Its involvement in cell proliferation, migration, invasion and tumor growth also intimate functional involvement of galectin-1 in the progression of thyroid carcinoma, suggesting its potential as a therapeutic target PMID: 28677745
  14. This study showed that obese children had significantly higher galectin-1 levels in proportion to fat mass in obese cases than those in healthy children, which may be interpreted as a compensatory increase in an attempt to improve glucose metabolism. PMID: 28728946
  15. We further demonstrated using the NMR-based hydrogen-deuterium exchange (HDX) that lactose binding increases the exchange rates of residues located on the opposite side of the ligand-binding pocket for hGal1 and hGal8(NTD), indicative of allostery. Additionally, lactose binding induces significant stabilisation of hGal8(CTD) across the entire domain PMID: 28813004
  16. our findings indicate that galectin-1 plays a pivotal role in the regulation of key processes in cancer cells, such as migration, invasion, and chemoresistance, by modulating FAK and ERK signaling and survivin level. PMID: 28415760
  17. Gal-3 staining in the nucleus could be a new positive prognosticator for ovarian cancer. PMID: 28594391
  18. Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade. PMID: 28473314
  19. markedly increased brain Gal-1 and S-nitrosylated Gal-1 both in scrapie-infected rodents and human prion diseases. PMID: 27211330
  20. Gal-1 knockdown dramatically improved drug sensitivity of breast cancer by reducing P-glycoprotein (P-gp) expression via inhibiting the Raf-1/AP-1 pathway, providing a novel therapeutic target to overcome MDR in breast cancer. PMID: 28212576
  21. the immunosuppressive microenvironment promoted by hepatic stellate cell-derived galectin-1 in hepatocellular carcinoma can be inhibited by miR-22 PMID: 27494859
  22. Galectin-1 promotes invasion and epithelial mesenchymal transformation in gastric cancer cells via activation of the non-canonical Hh pathway in Gli-1 dependent manner. PMID: 27835885
  23. Gal-1 level retained independent predictive influence on the risk of developing cGvHD PMID: 27214079
  24. this study identified 131 Gal-3 and 15 Gal-1 interactors by galectin pulldown experiments combined with quantitative proteomics. PMID: 28576849
  25. we found that galectin-1 was a novel modulator of MDR1 by proteomic analysis of a model system of leukemia cell lines PMID: 27050374
  26. Data found Gal-1 to induce EMT and gastric cancer (GC) cell migration and invasion. Also, Gal-1 up-regulated Gli1 expression and beta1 integrin was responsible for Gal-1-induced Gli1 expression and EMT. PMID: 27836001
  27. Galectin-1-driven production of SDF-1 in pancreatic stellate cells through activation of NF-kappaB promotes metastasis in pancreatic ductal adenocarcinoma. PMID: 28336327
  28. Gal-1 expression by MM cells was upregulated in hypoxic conditions and stable knockdown of hypoxia inducible factor-1alpha significantly downregulated its expression PMID: 27311934
  29. Gal1 may be a useful marker for determining whether morphologic changes in oral cells are reactive or neoplastic PMID: 26980012
  30. The aim of this study was to analyze the syncytium formation abilities of BeWo cells that were gal-1 silenced. PMID: 26418280
  31. Studies provide evidence that galectin-1 belongs to the group of potential pathogenic molecules in systemic lupus erythematosus. [review] PMID: 28100106
  32. an intact dimer interface of Gal-1 is required for it to positively regulate H-rasG12V nanoclustering, but negatively K-rasG12V nanoclustering. PMID: 27087647
  33. Our results suggest that Gal-1 and ASPP2 functionally compete in nanocluster for active Ras on the plasma membrane. ASPP2 dominates the biological outcome, thus switching from a Gal-1 supported growth-promoting setting to a senescence inducing and stemness suppressive program in cancer cells. Our results support Ras nanocluster as major integrators of tumour fate decision events. PMID: 27437940
  34. Galectin-1 and Galectin-3 are novel-binding partners for human FVIII. Gal-1 binding can influence the procoagulant activity of FVIII. PMID: 27013611
  35. Proteomics of the interstitial fluid in subcutaneous adipose tissue in vivo identified a novel adipokine, galectin-1, with a potential role in the pathophysiology of type 2 diabetes. PMID: 27282870
  36. Suggest that galectin-1 is a protective factor against the development of digital vasculopathy in systemic sclerosis. PMID: 24517166
  37. This study demonstrated that TLR-mediated PI3K activation modulated the invasion and metastasis of ovarian cancer through the production of galectin-1. PMID: 28350104
  38. Gal-1-regulated carcinoma-associated fibroblast activation promotes breast cancer cell metastasis by upregulating MMP-9 expression. PMID: 27025601
  39. It is a beta-galactose-binding animal lectin and known to be distributed throughout the body. PMID: 27590897
  40. Our functional analyses of galectin-1 in urinary bladder urothelial carcinoma provided novel insights into the critical role of galectin-1 in tumor progression and invasion. These results revealed that silencing the galectin-1-mediated MAPK signaling pathway presented a novel strategy for bladder cancer therapy. PMID: 27440446
  41. the TLR4/Gal-1 signaling pathway regulates lactate-mediated EMT processes through the activation of ADAM10 and ADAM17 in colon cancer cells. PMID: 27837433
  42. These findings suggest that Gal-1 plays an important role in immune escape of gingival squamous cell carcinoma cells, and Gal-1 expression level may be a useful clinicopathological prognostic marker for this cancer. PMID: 28108653
  43. Galectin-1 gene silencing would improve the sensitivity of A549/DDP cells to cisplatin in vivo and in vitro. PMID: 27392028
  44. In this study, gal-1, -2, -3 and -13 were investigated systematically in the trophoblast and decidua compartment of intrauterine growth restriction (IUGR) placentas and normal third trimester control placentas and stratified by fetal gender and gestational age. Gal-1 Expression Shows No Significant Changes in IUGR Placentas in Villous Trophoblasts. PMID: 27070577
  45. Galectin-1 overexpression activates the FAK/PI3K/AKT pathway by upregulating expression of alphavbeta3 integrin, leading to enhanced hepatocellular carcinoma invasion via epithelial-mesenchymal transition and sorafenib resistance. PMID: 27100895
  46. results show that HELLP syndrome is associated with increased circulating levels of gal-1 PMID: 26956510
  47. The integrative analysis of galectins(Gal-1, -3, -4, -9) discriminated IBD from other intestinal inflammatory conditions and could be used as potential mucosal biomarker PMID: 26891020
  48. Galectin-1 was undetectable in normal and ulcerative colitis colonic epithelium, while galectin-2, galectin-3, and galectin-4 were strongly expressed. PMID: 26885508
  49. Tumor-driven, unremitting expression of Satb1 in activated Zbtb46+ inflammatory dendritic cells that infiltrate ovarian tumors results in an immunosuppressive phenotype characterized by increased secretion of tumor-promoting Galectin-1 and IL-6. PMID: 26876172
  50. Epithelial immunostaining for galectin-1 tended to be elevated in fallopian tubes from women with ectopic pregnancy. PMID: 26359845

Show More

Hide All

Subcellular Location Secreted, extracellular space, extracellular matrix
Tissue Specificity Expressed in placenta, maternal decidua and fetal membranes. Within placenta, expressed in trophoblasts, stromal cells, villous endothelium, syncytiotrophoblast apical membrane and villous stroma. Within fetal membranes, expressed in amnion, chorioamnioti
Database Links

HGNC: 6561

OMIM: 150570

KEGG: hsa:3956

STRING: 9606.ENSP00000215909

UniGene: Hs.445351

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1